Reuters logo
13 days ago
BRIEF-Cara Therapeutics says ‍phase 1 results showed all four tablet strengths of oral CR845 were generally well-tolerated​
July 12, 2017 / 11:41 AM / 13 days ago

BRIEF-Cara Therapeutics says ‍phase 1 results showed all four tablet strengths of oral CR845 were generally well-tolerated​

1 Min Read

July 12 (Reuters) - Cara Therapeutics Inc

* Cara Therapeutics announces summary data from phase 1 trial of oral cr845 in hemodialysis patients with chronic kidney disease

* Cara Therapeutics Inc - ‍phase 1 results showed that all four tablet strengths of oral CR845 were generally well-tolerated​

* Cara Therapeutics- ‍overall,frequency of treatment emergent adverse events (teaes) in CR845-treated patients was similar to group administered placebo​

* Cara Therapeutics-data to inform design of planned oral CR845 pruritus clinical program in non-dialysis ckd-ap population aimed to initiate later this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below